Complete title: A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib
|Research Study Number||20130857|
|Principal Investigator||William Harris|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Liver Cancer; Solid Tumors
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.